Bespak expands next-generation nasal offering with launch of NasaDose
Holmes Chapel, UK, 1 October 2026 – Bespak®, the specialist inhalation contract development and manufacturing organisation (CDMO) focused exclusively on inhaled and nasal drug delivery, today announced the continued expansion of its next-generation nasal drug delivery offering with the launch of NasaDose® Ultra Soft Unit Dose Spray, a device that combines Bespak’s established NasaDose unit dose platform with proprietary soft mist technology from its joint venture, Resyca®.
The launch of NasaDose Ultra Soft Unit Dose Spray further strengthens Bespak’s expanded nasal drug delivery offering. It follows Bespak’s recently announced collaboration with Upperton, a specialist formulation development CDMO, which brings together expertise in formulation, device engineering, clinical supply and commercial manufacture. Together with specialist technologies from partners including Resyca, the offering supports liquid, soft mist and dry powder nasal products from early development through to commercial supply.
The NasaDose Ultra Soft Unit Dose Spray combines, for the first time, differentiated drug delivery technologies from Bespak and Resyca to create a unique intranasal delivery solution for gentle yet precise nasal delivery. Resyca’s soft mist technology generates a fine, low-velocity nasal spray providing consistent aerosol performance with low mechanical shear, supporting the delivery of sensitive and complex formulations. Bespak’s spring-powered actuation mechanism is engineered to deliver a repeatable dose largely independent of user actuation speed, reducing operator variability and supporting consistent performance. The device allows key performance parameters, including spray characteristics, dose volume and actuation force, to be configured according to formulation requirements and target patient populations, and enables precise and controlled deposition within the nasal cavity, including targeted delivery to the turbinate and olfactory regions.
The NasaDose Ultra Soft Unit Dose Spray is designed to support the delivery of both conventional small molecules and formulations including proteins, peptides and other complex biologics that may be susceptible to degradation during aerosolisation, making it suitable for applications including local nasal therapies, prophylaxis, vaccines and systemic delivery, with particular potential for nose-to-brain and CNS therapies.
Chris Hirst, CEO of Bespak said: “Nasal drug delivery is an exciting and rapidly evolving area, with developers exploring new ways to deliver increasingly complex therapies. NasaDose Ultra Soft Unit Dose Spray brings together our established NasaDose platform with Resyca’s proprietary soft mist technology, expanding the options available to customers developing the next generation of nasal therapies. Combined with our growing formulation and development capabilities, this gives customers a strong platform to progress promising nasal drug products from early development towards clinical and commercial supply.”
Deborah Jones, CEO, Resyca said: “When developing nasal therapies, particularly for sensitive and complex formulations, the choice of delivery device can be just as important as the formulation itself. Our existing Ultra Soft Nasal Spray device has already demonstrated the value of soft mist sprays for nasal drug delivery. NasaDose Ultra Soft Unit Dose Spray brings that technology into a unit dose format, adding an option for therapies where a single dose is preferred or required.
Together, our multi dose and unit dose soft mist devices give developers more flexibility to choose a delivery system that suits their therapy and the needs of patients.”
Learn more at: https://bespak.com/platforms/nasadose-ultra-soft-unit-dose
About Bespak
Bespak is a specialist global contract development and manufacturing organisation (CDMO) solely focused on the inhaled and nasal drug delivery industry. It develops and manufactures inhaled and nasal drug products, drug delivery devices and components for the global pharmaceutical market. Headquartered in Holmes Chapel, UK, Bespak provides a specialist, fully integrated service to support customers from early-stage feasibility, analytical and formulation, product development and clinical supply, through to full-scale cGMP batch production.
Built on established expertise but ready for the future, Bespak is a long-term innovation partner committed to driving sustainability in the industry. With expertise spanning pressurised Metered Dose Inhalers, Soft Mist Inhalers, and Dry Powder Inhalers for respiratory conditions, the company also specialises in intranasal drug delivery with device technologies, product development and manufacturing capabilities supporting liquid, powder and soft mist delivery platforms.
Bespak will unveil its expanded nasal offering at CPHI 2026 in Milan, demonstrating how its new capabilities can support nasal drug products from development through to commercialisation. Visitors can meet the Bespak team at stand 11C27 to discuss their nasal development programmes.
More information: www.bespak.com
About Resyca
Resyca is redefining drug delivery with its next‑generation soft mist inhalers and soft nasal sprays. Founded in 2020 as a joint venture between Medspray and Bespak, Resyca develops advanced, proprietary delivery platforms that integrate Medspray’s micro‑nozzle technology.
With Resyca’s delivery devices, pharmaceutical partners can clearly differentiate their therapies through highly efficient pulmonary delivery and precise nasal administration — making Resyca’s platforms an excellent fit for a broad spectrum of drug-device combination products.
To further accelerate development and commercialisation, Resyca supports pharmaceutical partners with a comprehensive suite of services spanning early‑stage development through to full commercial launch.
More information: www.resyca.com
